Koers Wayland Group Corp Canadian Securities Exchange
Aandelen
CA5667241007
Farmaceutische producten
Omzet 2016 | 4,06 5,53 3,73 | Omzet 2017 | 3,22 4,39 2,96 | Marktkapitalisatie | 203 mln. 277 mln. 187 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2016 | -8 mln. -10,9 mln. -7,36 mln. | Nettowinst (verlies) 2017 | -67 mln. -91,27 mln. -61,63 mln. | EV/omzet 2016 * | - |
Nettoschuld 2016 | 9,13 12,44 8,4 | Nettoliquiditeiten 2017 | 0,42 0,57 0,38 | EV/omzet 2017 | 63.046.727 x |
K/w-verhouding 2016 * |
-
| K/w-verhouding 2017 |
-2,13
x | Werknemers | - |
Dividendrendement 2016 * |
-
| Dividendrendement 2017 |
-
| Vrij verhandelbaar | 100% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Ben Ward
CEO | Chief Executive Officer | 44 | - |
Dan Healey
COO | Chief Operating Officer | - | - |
Steven Bennett
CTO | Chief Tech/Sci/R&D Officer | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Ben Ward
CEO | Chief Executive Officer | 44 | - |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+41,06% | 6,19 mld. | |
-15,95% | 4,48 mld. | |
+6,36% | 3,29 mld. | |
-11,34% | 3,12 mld. | |
-3,12% | 2,5 mld. | |
+45,41% | 1,94 mld. | |
-7,74% | 1,68 mld. | |
-0,67% | 1,64 mld. | |
-11,32% | 1,56 mld. |